1. Listing of included trials.

Valency	Phase	Number of trials	Appelation	N	Outcomes	Main References
Monovalent	II	1	Phase2 trial (ph2,1v)	2392	Efficacy, safety	Koutsky 2002 Mao 2006 Rowhani‐Rahbar 2009
Bivalent	II	2	Japanese trial (ph2,2v)	1040	Efficacy, safety	Konno 2010 Konno 2010a Konno 2014
			Phase2 trial (ph2,2v)	1113	Efficacy, safety	Harper 2004 Harper 2006 The GSK Study Group 2009 De Carvalho 2010
	III	16	African_2 country trial (ph3,2v)	676	Safety	Sow 2013
			Chinese trial (ph3,2v)_young	6051	Efficacy, safety	Zhu 2014
			Chinese trial (ph3,2v)_ adolescent	750	Safety	Zhu 2014a
			Chinese trial (ph3,2v)_mid‐adult	1212	Safety	Zhu 2014a
			Co‐vaccination_dTpa_IPV trial (ph3,2v)	494	Safety	Garcia‐Sicilia 2010
			Co‐vaccination_HAB trial (Ph3, 2v)	494	Safety	Pedersen 2012
			Co‐vaccination_HepB trial (ph3, 2v)	541	Safety	Schmeink 2011
			CVT (ph3,2v)	7466	Efficacy, safety	Herrero 2011 Kreimer 2011
			Hong Kong trial (ph3,2v)	294	Safety	Ngan 2010
			Immunobridging(ph3,2v)	2067	Safety	Medina 2010
			Indian trial (ph3,2v)	354	Safety	Bhatla 2010
			Korean trial (ph3,2v)	208	Safety	Kim 2010
			Korean trial (ph3b,2v)	321	Safety	Kim 2011
			Malaysian trial (ph3,2v)	271	Safety	Lim 2014
			PATRICIA trial (ph3,2v)	18,644	Efficacy, safety	Paavonen 2007 Paavonen 2009 Szarewski 2011 Wheeler 2011 Lehtinen 2012
			VIVIANE trial (ph3,2v)	5752	Efficay, safety,	Skinner 2014 Wheeler 2016
Quadrivalent	II	3	Japanese trial (ph2,4v)	1021	Safety	Yoshikawa 2013
			Korean trial (ph2,4v)	176	Safety	Kang 2008
			Phase2 trial (ph2,4v)	552	Efficacy, safety	Villa 2005 Villa 2006 Villa 2006a Olsson 2009
	III	4	African_3 country trial (ph3,4v)	98	Safety	Mugo 2015
			FUTURE I trial (ph3,4v)	5455	Efficacy, safety	Garland 2007
			FUTURE II trial (ph3,4v)	12,167	Efficacy, safety	FUTURE‐II 2007
			FUTURE III trial (ph3,4v)	3819	Efficacy, safety	Munoz 2009 Castellsagué 2011
Total		26		73,428